Crescent Biopharma
CBIO
84 hedge funds and large institutions have $747M invested in Crescent Biopharma in 2018 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 31 increasing their positions, 21 reducing their positions, and 24 closing their positions.
51% more call options, than puts
Call options by funds: $1.53M | Put options by funds: $1.01M
48% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 21
6% more capital invested
Capital invested by funds: $707M → $747M (+$40.6M)
0.03% more ownership
Funds ownership: 1.06% → 1.09% (+0.03%)
0% more funds holding
Funds holding: 84 → 84 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$27.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$9.92M |
| 3 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$8.68M |
| 4 |
O
OppenheimerFunds
New York
|
+$7.85M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$5.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCI
Columbus Circle Investors
|
-$9.11M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$4.68M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$4.35M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$4.06M |
| 5 |
Goldman Sachs
New York
|
-$3.54M |
CBIO Hedge Fund Activity: Q2 2018 in Review
84 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q2 2018, worth a combined $747M — up 5.8% from $707M a quarter earlier.
Fund positioning in CBIO was balanced in Q2 2018: 24 funds opened new positions, 24 closed out, 31 added to existing stakes and 21 trimmed.
The largest buyer was BlackRock, adding an estimated $27.8M. The largest seller was Columbus Circle Investors, exiting entirely with an estimated $9.11M sold.
- 84 institutional investors held Crescent Biopharma (CBIO) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $747M of Crescent Biopharma stock for Q2 2018, up 5.8% quarter-over-quarter.
- 24 funds opened new Crescent Biopharma positions in Q2 2018 and 24 closed out, a net change of 0 holders.
- The largest Crescent Biopharma buyer in Q2 2018 was BlackRock, an estimated $27.8M added.
- The largest Crescent Biopharma seller in Q2 2018 was Columbus Circle Investors, an estimated $9.11M sold.
Based on aggregated 13F filings for Q2 2018.